Haiyan Jia, Jiajia Mai, Min Wu, Hong Chen, Xiaojiao Li, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yue Hu, Xiaoxue Zhu, Xiuhong Jiang, Bo Hua, Tian Xia, Gang Liu, Aiyun Deng, Bo Liang, Ruoling Guo, Hui Lu, Zhe Wang, Huanming Chen, Zhijun Zhang, Hong Zhang, Junqi Niu, Yanhua Ding
BACKGROUND: Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluated in patients with CHB. METHODS: This study was a double-blind, randomized, placebo-controlled phase 1b trial in Chinese CHB patients. Noncirrhotic and treatment-naive CHB patients were divided into three cohorts (10 patients per cohort) and randomized within each cohort in a ratio of 4:1 to receive a single dose of 50, 100, or 200 mg of Canocapavir or placebo once a day for 28 consecutive days...
March 16, 2023: BMC Medicine